The International Tennis Integrity Agency (ITIA) notes today’s decision from the Court of Arbitration for Sport (CAS) in the Tennis Anti-Doping Programme (TADP) case of British tennis player Tara Moore, who tested positive for anabolic steroids boldenone and nandrolone in April 2022.
In December 2023, an independent tribunal determined that Moore bore No Fault or Negligence for their Adverse Analytical Findings and therefore was not subject to a period of ineligibility.
CAS upheld the ITIA’s appeal against the first instance No Fault or Negligence ruling with respect to nandrolone, issuing Moore with a four-year period of ineligibility – with a credit for time served under provisional suspension.
ITIA Chief Executive Officer Karen Moorhouse said: “For the ITIA, every case is considered according to the individual facts and circumstances.
“Our bar for appealing a first instance decision is high, and the decision is not taken lightly. In this case, our independent scientific advice was that the player did not adequately explain the high level of nandrolone present in their sample. Today’s ruling is consistent with this position.
“We understand that players and their support teams may have questions about this decision, and we will answer these fully once we have reviewed the details of the ruling.”
Ends
Published 15 July 2025 19:00
